A road map for leptospirosis research and health policies based on country needs in Latin America

Hoja de ruta para la investigación sobre la leptospirosis y para las políticas de salud basadas en las necesidades de los países en América Latina

Guia para pesquisa e políticas de saúde em leptospirose com base nas necessidades dos países na América Latina

Martha Maria Pereira Maria Cristina Schneider Claudia Munoz-Zanzi Federico Costa Jackie Benschop Rudy Hartskeerl Julio Martinez Michel Jancloes Eric Bertherat About the authors

ABSTRACT

This report summarizes the presentations, discussions and the recommendations coming from the Oswaldo Cruz Institute/FIOCRUZ International Workshop for Leptospirosis Research Based on Country Needs and the 5th Global Leptospirosis Environmental Action Network meeting, which was held in the city of Rio de Janeiro, Brazil, 10–12 November 2015. The event focused on health policy and worked to develop a road map as a consensus document to help guide decision-making by policymakers, funding bodies, and health care professionals. The direction that leptospirosis research should take in the coming years was emphasized, taking into account the needs of countries of Latin America, as well as experiences from other world regions, as provided by international experts. The operational concepts of “One Health” and translational research underlaid the discussions and the resulting recommendations. Despite the wide geographic distribution of leptospirosis and its impact in terms of incidence, morbidity, and mortality, leptospirosis is not yet considered a “tool-ready” disease for global initiatives. Surveillance programs need new tools and strategies for early detection, prevention, and follow-up. The major recommendations developed at the Rio meeting cover both health policy and research. The health policy recommendations should be taken into account by decisionmakers, government officials, and the Pan American Health Organization. The priorities for research, technological development, and innovation should be considered by research institutions, universities, and stakeholders.

Keywords
Leptospirosis; health planning guidelines; health services research; Latin America

RESUMEN

En este informe se resumen las ponencias, los debates y las recomendaciones del taller internacional para la investigación sobre la leptospirosis basada en las necesidades de los países organizado por el Instituto Oswaldo Cruz/FIOCRUZ y la quinta reunión de la Red Global de Acción Ambiental contra la Leptospirosis, que se celebró en la ciudad del Rio de Janeiro (Brasil), del 10 al 12 de noviembre del 2015. El evento se centró en las políticas de salud y en la elaboración de una hoja de ruta que sirviese como un documento guía consensuado para la toma de decisiones de los formuladores de políticas, los organismos de financiamiento y los profesionales de la salud. Se hizo hincapié en la dirección que tiene que tomar la investigación sobre la leptospirosis en los próximos años, en la que se deben tener en cuenta las necesidades de los países de América Latina, así como a las experiencias de otras regiones del mundo, de acuerdo con las consideraciones de los expertos internacionales. Los conceptos operativos de “Una sola salud” y de la investigación traslacional fueron la base de los debates y de las recomendaciones resultantes. A pesar de la extensa distribución geográfica de la leptospirosis y su repercusión desde el punto de vista de la incidencia, la morbilidad y la mortalidad, la leptospirosis no se considera todavía una enfermedad con herramientas listas para ser aplicadas (tool-ready) en las iniciativas a nivel mundial. Los programas de vigilancia necesitan herramientas y estrategias nuevas para llevar a cabo la detección temprana, la prevención y el seguimiento. Las recomendaciones principales que se emitieron en la reunión de Rio cubrieron tanto el ámbito de las políticas de salud como el de la investigación. Las recomendaciones que se refieren a las políticas de salud deben ser tenidas en cuenta por los encargados de tomar decisiones, los funcionarios de gobierno y la Organización Panamericana de la Salud. Las prioridades de la investigación, el desarrollo tecnológico y la innovación deben ser incorporadas por las instituciones de investigación, las universidades y los interesados directos.

Palabras clave
Leptospirosis; directrices para la planificación en salud; investigación en servicios de salud; América Latina

RESUMO

Trata-se de um resumo das apresentações, debates e recomendações do Workshop Internacional para Pesquisa em Leptospirose com Base nas Necessidades dos Países do Instituto Oswaldo Cruz/FIOCRUZ e 5a Reunião da Rede Global de Ação Ambiental em Leptospirose, realizados na cidade do Rio de Janeiro, Brasil, de 10 a 12 de novembro de 2015. Os participantes do evento debateram políticas de saúde e elaboraram um guia como documento de consenso para orientar a tomada de decisão pelos responsáveis por políticas, agências de financiamento e profissionais da saúde. Destacou-se o rumo a ser tomado em pesquisa em leptospirose nos próximos anos levando em consideração as necessidades dos países da América Latina, assim como as experiências de outras regiões do mundo, conforme estabelecido por especialistas internacionais. Os conceitos práticos da perspectiva “One Health” (Um Mundo, Uma Saúde) e pesquisa translacional foram a base dos debates e das recomendações conseguintes. Apesar da ampla distribuição geográfica e do seu impacto em termos de incidência, morbidade e mortalidade, a leptospirose ainda não é considerada uma doença “tool ready” para iniciativas globais. Os programas de vigilância precisam de novas ferramentas e estratégias para detecção precoce, prevenção e acompanhamento. As principais recomendações elaboradas na reunião do Rio englobam política de saúde assim como pesquisa e elas devem ser levadas em consideração pelas autoridades, funcionários do governo e Organização Pan-Americana da Saúde. As instituições de pesquisa, universidades e interessados diretos devem atentar para as prioridades em pesquisa, desenvolvimento tecnológico e inovação.

Palavras-chave
Leptospirose; diretrizes para o planejamento em saúde; pesquisa sobre serviços de saúde; América Latina

Leptospirosis is a disease that has a significant health impact in various regions of the world and that affects people from different socioeconomic levels. This zoonotic disease of epidemic potential has been causing outbreaks for many years, mainly related to heavy rain events in geographic areas prone to flooding (11 Trevejo RT, Rigau-Pérez JG, Ashford DA, McClure EM, Jarquín-González C, Amador JJ, et al. Epidemic leptospirosis associated with pulmonary hemorrhage—Nicaragua, 1995. J Infect Dis. 1998;178(5):1457–63.66 Schneider MC, Nájera P, Aldighieri S, Bacallao J, Soto A, Marquiño W, et al. Leptospirosis outbreaks in Nicaragua: identifying critical areas and exploring drivers for evidence-based planning. Int J Environ Res Public Health. 2012;9(11):3883–910.). Leptospirosis is also considered a neglected disease that is associated with populations living in vulnerable conditions in urban and rural settings. Many leptospirosis cases are related to specific occupations, such as farming and handling animals (77 Ko AI, Reis MG, Dourado CMR, Johnson Jr WD, Riley LW. Urban epidemic of severe leptospirosis in Brazil. Lancet. 1999;354(9181):820–5.1010 Benschop J, Heuer C, Jaros P, Collins-Emerson J, Midwinter A, Wilson P. Sero-prevalence of leptospirosis in workers at a New Zealand slaughterhouse. N Z Med J. 2009;122(1307):39–47.). Despite the increasing number of cases and outbreaks globally, leptospirosis remains relatively unrecognized (1111 Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):1–19., 1212 Schneider MC, Jancloes M, Buss DF, Aldighieri S, Bertherat E, Najera P, et al. Leptospirosis: a silent epidemic disease. Int J Environ Res Public Health. 2013;10(12):7229–34.).

Leptospirosis in humans is associated with a high number of cases, as well as high morbidity and fatality rates. Concerns about animal leptospirosis are related to its impact on animal health, to economic losses, and to risk situations in the human-animal-ecosystem interface. Even with the progress made by researchers and government authorities, there are still important knowledge gaps that hinder both surveillance efforts and prevention and control activities.

One step toward filling those knowledge gaps came with the International Workshop of the Oswaldo Cruz Institute/FIOCRUZ for Leptospirosis Research Based on Country Needs and 5th Global Leptospirosis Environmental Action Network (GLEAN) meeting, which was held in the city of Rio de Janeiro, Brazil, 10-12 November 2015. The meeting focused on health policy, with the objective of developing a road map for leptospirosis research based on country needs. The 50 attendees included policymakers, health professionals, and researchers from the Americas, Europe, Asia, and Africa, as well as New Zealand. The discussions were comprehensive, involving experts from multiple disciplines, with noteworthy contributions on specific topics.

Novel aspects of the meeting

The main purpose of the meeting was to find ways to change the current situation of leptospirosis from a disease that is neglected, but not listed as such by the World Health Organization (WHO), into a “tool-ready” disease for global initiatives. The meeting efforts to assess country needs and the state of the art with respect to leptospirosis were mainly focused on Latin America, but health professionals, decisionmakers, and researchers from other world regions also contributed with their knowledge and experiences. This integrated approach in a highly specialized international forum led to extensive discussions and to results that may represent a turning point for developments in the area of leptospirosis in the near future.

Leptospirosis as a “tool-ready” disease

An infectious disease that can be controlled or even eliminated through mass administration of safe and effective treatment or other effective interventions, such as vaccines, is considered to be a “tool-ready” disease.

A disease that does not yet have easy tools for interventions is more difficult for decision makers to select as a priority for government agendas, even if its prevalence is high, due to the uncertainty in the outcome of a systematic or large-scale control program.

WHO and its partners developed a road map for neglected tropical diseases that are “tool-ready” (1313 World Health Organization. Global plan to combat neglected tropical diseases 2008–2015. Geneva: WHO; 2007., 1414 World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. Geneva: WHO; 2012.). Unfortunately, leptospirosis is not targeted in that initiative. Leptospirosis could be considered “tool-deficient” in many aspects, mostly due to the lack of an effective, easy, inexpensive diagnostic test and the absence of a human vaccine. However, leptospirosis may be associated with poverty and to certain types of environmental or occupational risks. Therefore, developing both an early detection tool and a vaccine are crucial to saving lives.

METHODS

The prioritization of health and research topics for the Rio meeting was based on the nominal group technique. The meeting attendees consisted of 20 decision makers (composed of 9 country representatives, 6 participants from other positions such as veterinary doctor or biologist working at the government not in managerial position and 5 representatives from international organizations); 20 researchers in leadership positions at their respective institutions; 2 postgraduate students with data relevant to the meeting; and 8 administrative-staff members from FIOCRUZ and the Pan American Health Organization (PAHO).

PAHO had invited 10 countries from Latin America to the meeting, and 9 of them sent a national representative responsible for leptospirosis to the event: Argentina, Brazil, Colombia, Costa Rica, Cuba, Honduras, Mexico, Panama, and Peru. The countries had been selected based on the reported number of cases, cumulative leptospirosis incidence rates and alerts, and regional representation. Before the meeting, PAHO had sent a survey to the country representatives, asking for more disaggregated epidemiological information and for answers to a questionnaire designed to identify country needs for surveillance and other key concerns, as well their views about possible solutions involving research, technological development, and innovation (RTDI) (Supplementary File 1).

PAHO combined the countries’ responses and prepared summaries to be presented at the beginning of each meeting session. Although those responses were all from Latin America, the presence of experts from other world regions at the meeting made it possible to identify shared needs and challenges.

The authors of this article obtained additional baseline data about the leptospirosis epidemiological situation in the different countries from the experts’ presentations at the Rio meeting. This information included the first set of regional leptospirosis data from the PAHO core indicators database as well as the responses to the PAHO questionnaires, which seven of the nine national representatives completed and returned.

After the Rio meeting, the authors drew up the road map and the recommendations, using the information from the event, including papers, slides, and recorded oral presentations and discussions, as well as a search for other, relevant scientific literature. The criteria for analysis, prioritization, and recommendations for health issues and RTDI included: 1) the magnitude of the problem in Latin America and in other areas of the world; 2) the impact on human and animal health, considering the One Health approach; and 3) the probability that the current technology and available resources could change the present situation.

RESULTS

Prediction

Leptospirosis as an emerging and neglected disease

During the meeting, recent studies were presented on the global public health burden of leptospirosis. It is estimated that every year over 1 million cases and 59 000 deaths occur due to the disease (1111 Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):1–19.). Males account for approximately 80% of the total burden. A study by Torgerson and colleagues (1515 Torgerson PR, Hagan JE, Costa F, Calcagno J, Kane M, Martinez-Silveira MS, et al. Global burden of leptospirosis: estimated in terms of disability adjusted life years. PLoS Negl Trop Dis. 2015;9(10):e0004122.) found that the greatest burden is in the poorest countries in tropical regions. That study also predicted a high burden in regions such as Africa, where only limited data are available. In addition, those researchers estimated that, globally, nearly 2.90 million disability-adjusted life years (DALYs) are lost each year (with 2.80 million years of life lost due to mortality, and over 100 000 years lived with a disability) (1515 Torgerson PR, Hagan JE, Costa F, Calcagno J, Kane M, Martinez-Silveira MS, et al. Global burden of leptospirosis: estimated in terms of disability adjusted life years. PLoS Negl Trop Dis. 2015;9(10):e0004122.).

For most of the countries and territories of Latin America and the Caribbean that are located in tropical and subtropical areas, leptospirosis is emerging as a public health problem. A study conducted using information from HealthMap (a global database that utilizes various online sources for real-time surveillance of emerging public health threats) found that 63% of the global alerts on leptospirosis between the years 2007 and 2013 were reported in the Region of the Americas (1212 Schneider MC, Jancloes M, Buss DF, Aldighieri S, Bertherat E, Najera P, et al. Leptospirosis: a silent epidemic disease. Int J Environ Res Public Health. 2013;10(12):7229–34.). However, comprehensive data on leptospirosis cases are also limited in the Americas. In 2015, PAHO included human leptospirosis in the Regional Core Health Data Initiative (1616 Pan American Health Organization. Regional Core Health Data Initiative. Available from: http://www.paho.org/hq/index.php?option=com_tabs&view=article&id=2151&Itemid=3632&lang=en Accessed 16 August 2016.
http://www.paho.org/hq/index.php?option=...
), and information from that source was presented during the Rio meeting. A journal article (1717 Schneider MC, Leonel DG, Hamrick PN, Caldas EP, Velásquez RT, Mendigaña Paez FA, et al. Leptospirosis in Latin America: exploring the first set of regional data. Rev Panam Salud Publica.2017;41:e81.) on the first year’s data indicated that more than 10 000 human cases were reported in the Region of the Americas.

A systematic review of the epidemiology of leptospirosis in Africa (1818 Allan KJ, Biggs HM, Halliday JEB, Kazwala RR, Maro VP, Cleaveland S, et al. Epidemiology of leptospirosis in Africa: a systematic review of a neglected zoonosis and a paradigm for “One Health” in Africa. PLoS Negl Trop Dis. 2015;9(9):e0003899.) showed that while human disease data are lacking from many countries, there is evidence that leptospirosis is an important cause of febrile disease in that continent. The prevalence of leptospirosis among acute febrile patients ranged from 2.3% to 19.8%. Based on information from several studies, it was estimated that for the entire continent of Africa, the caseload could be up to 750 000 leptospirosis cases per year. It was also concluded that in Africa leptospirosis is endemic in both wild and domestic animals.

Leptospirosis is currently not included in the World Organisation for Animal Health (OIE) list of terrestrial animal diseases under surveillance. A geographic distribution and mapping of outbreaks in the Americas (1919 Petrakovsky J, Bianchi A, Fisun H, Nájera-Aguilar P, Pereira MM. Animal leptospirosis in Latin America and the Caribbean countries: reported outbreaks and literature review (2002–2014). Int J Environ Res Public Health. 2014;11(10):10770–89.) showed that the disease is widely disseminated. Tropical terrestrial biomes are the predominant ecosystems associated with animal leptospirosis outbreaks. Several animal species (synanthropic rodents, domestic livestock, and wild animals) have serological evidence of infection or are carriers for Leptospira. The morbidity and the health impact associated with leptospirosis in livestock are expected to cause economic losses, but there are insufficient studies to properly quantify those costs.

Knowing where and when the risk is higher

As with many others infectious diseases, leptospirosis displays patterns in its spatial and temporal distribution that are driven by a complex web of socioecological factors. The goal of epidemiological and predictive mathematical modeling is to build knowledge about the mechanisms behind the observed patterns of infection. That research can improve our understanding of the occurrence of leptospirosis outbreaks and also identify high infection risk areas. A study using an ecosystem approach in the state of Rio Grande do Sul, Brazil, was described in one of the Rio meeting presentations. That research found the areas with the highest incidences of infection and also identified a set of environmental factors as the main predictors of disease—information that can be used to support better interventions (2020 Schneider MC, Najera P, Pereira MM, Machado G, dos Anjos CB, Rodrigues RO, et al. Leptospirosis in Rio Grande do Sul, Brazil: an ecosystem approach in the animal-human interface. PLoS Negl Trop Dis. 2015;9(11):e0004095.). Another Rio presentation concerned a portfolio management model being developed to compare interventions for leptospirosis and to identify optimal choices under different conditions, by using complex system analysis and computational technology.

Detection

Current tools and emerging technologies for leptospirosis diagnosis

Conventional laboratory diagnostic tests that are currently used as global standards and references have many drawbacks. These shortcomings include delayed results, unreliability, a low detection threshold, difficult standardization, and requiring well-trained personnel and/or expensive media and equipment. The microscopic agglutination test (MAT) is considered to be the gold standard for serological diagnosis. However, it has only 80% sensitivity, and the confirmation of clinical suspicion may be late for clinical management. Due to the tedious growth of Leptospira, isolation using culture is slow and sensitivity is lower than with serological tests. The identification of Leptospira at the species and serovar levels is important for epidemiological knowledge, but the tools and expertise are restricted to a few reference laboratories around the world.

The rapid diagnostic tests currently available usually have low diagnostic accuracy and thus require confirmation by conventional tests. Techniques based on nucleic acid amplification may provide early diagnosis since they are more sensitive than isolation in culture media. Diagnostic tests to be developed in the next 5 to 10 years should be easy to perform, should provide early diagnosis, and should use portable devices for nucleic acid amplification or genome sequencing, in order to provide digital data and online transfer to clinicians and to surveillance systems.

It should be emphasized that the goals regarding the One Health approach may not be reached unless there are appropriate laboratory tools. One meeting presentation gave the example of laboratory-based surveillance with algorithms built for proper sample collection and laboratory tests currently used (both commercially available and complementary ones) applied in the surveillance system in Brazil. A total of 24 057 reported cases and 2 023 deaths in the 2010-2015 period were confirmed by clinical and laboratorial criteria. In another Rio presentation related to the One Health approach, ongoing studies about leptospirosis diagnosis in animals in the Caribbean country of Saint Kitts and Nevis were highlighted.

It should be noted that leptospirosis can occur concomitantly with other diseases that need to be considered in the differential diagnosis during outbreaks or periods of increased incidence of dengue and dengue hemorrhagic fever, yellow fever, hantavirus, and hantavirus pulmonary syndrome. Clusters of leptospirosis cases and deaths from febrile hemorrhagic diseases occurring mainly in rural areas often go undiagnosed.

Leptospirosis surveillance in selected countries of Latin America

Of the nine Latin American countries with a national representative at the Rio meeting, seven of the nations had answered the PAHO survey. All seven of them include human leptospirosis as a disease of compulsory notification in their official surveillance systems. The internal flow of information commonly consists of daily alerts, with case reports sent to the central level and to laboratory for confirmation, according to each country’s guidelines. Some countries have established a committee to review the case reports and reach a final decision on them. Surveillance is an important component of the everyday activities under their national prevention and control programs.

At the Rio event, representatives from five countries described their epidemiological situation and surveillance system: Brazil, Colombia, Cuba, Honduras, and Peru. Table 1 summarizes that information.

TABLE 1
Reported leptospirosis cases and cumulative incidence in five Latin American countries, 2014

Prevention

Leptospirosis human vaccines

The rationale for developing vaccines for human and animal use is based on the health and economic impact of the disease and the lack of effective prevention and control measures, especially in rural areas. There are many vaccines used in veterinary practice, and there are two vaccines licensed for human use (from Cuba and France). However, the available vaccines are preparations of the whole bacterial cell. Protective immunity appears to be associated with anti-lipopolysaccharide (anti-LPS) antibodies. The four main limitations of the available vaccines for human use are: 1) the lack of robust evidence for their effectiveness; 2) adverse reactions that reduce the acceptability for human use; 3) short-term immunity; and 4) multivalent formulations that may not be appropriate for different epidemiological situations, since immunity is serovar-specific (2121 Srikram A, Zhang K, Bartpho T, Lo M, Hoke DE, Sermswan RW, et al. Cross-protective immunity against leptospirosis elicited by a live, attenuated lipopolysaccharide mutant. J Infect Dis. 2011 Mar 15;203(6):870–9. doi: 10.1093/infdis/jiq127.
https://doi.org/10.1093/infdis/jiq127...
).

The large number of serovars and species implicated in the etiology of leptospirosis has represented the greatest challenge to the development of vaccines. Recent efforts have focused on identifying candidates for subunit vaccines utilizing the high-throughput approaches currently available and applied to the development of new vaccines for several other bacterial pathogens. Such subunits of Leptospira as outer membrane proteins, virulence factors, and mediators of cellular interactions between pathogens and their natural hosts have been proposed. However, mediated immunity by vaccination, which provides cross-protection between serovars, is a goal to be achieved (2222 Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Micro. 2009;7(10):736–47., 2323 Sonrier C, Branger C, Michel V, Ruvoën-Clouet N, Ganière JP, André-Fontaine G. Evidence of cross-protection within Leptospira interrogans in an experimental model. Vaccine. 2000;19(1):86–94.).

Filling some knowledge gaps is important for developing and applying vaccines. Experimental models for proof of concept are based on death as the end point. There are limitations regarding the correlation between the model and the natural infection in humans or domestic animals. Evidence of natural immunity is indirect and currently consists of the detection of agglutinating antibodies. Key actions that are needed to meet the goal of having a new-generation vaccine were presented at the Rio meeting. These included carrying out more and more-targeted research, building partnerships between key stakeholders, conducting training at different levels, and encouraging investment.

Studies and interventions in animals

Studies and interventions in animals comprise an extensive field for research and actions related to health policy. It is known that rodent control is important for reducing the number of human cases. At the Rio event, representatives from Brazil presented the example of an integrated approach for rodent control. It includes education, training of health professionals, surveillance, risk stratification, control measures, and eco-epidemiological studies. This approach reduced rat infestation from 25% to 7% of households. Studies carried out in the African country of Niger that included trapping rodents and testing for leptospirosis found peculiar transmission patterns for the disease. Those patterns were mainly associated with urban gardens, calling attention to unexpected eco-epidemiological situations (2424 Dobigny G, Garba M, Tatard C, Loiseau A, Galan M, Kadaoure I, et al. Urban market gardening and rodent-borne pathogenic Leptospira in arid zones: a case study in Niamey, Niger. PLoS Negl Trop Dis. 2015;9(10):e0004097.).

The presentation from New Zealand during the Rio meeting included mention of the fact that leptospirosis had been recognized as an occupational problem there in the 1970s (when there was high incidence among dairy workers), and also later in the pig industry. Currently, the incidence of leptospirosis in humans in New Zealand is about 2.0 to 2.5 per 100 000, which is relatively high compared to other high-income countries. These cases are predominantly associated with agriculture, on which New Zealand is highly dependent economically, particularly the dairy, sheep, deer, and beef industries. Occupational infection is most common among meat industry workers and farmers. One measure for leptospirosis control that has been beneficial is the use of personal protection in farms. Another is vaccination in cattle, which has been shown to reduce shedding. Animal vaccination for leptospirosis in dairy farms has been commonplace in New Zealand for the past 40 years, and it is likely the most effective control measure.

Response

Human case management

At the Rio meeting, the experiences of Brazil, Peru, and Thailand in both endemic and epidemic situations were presented, with a focus on the challenges of medical practice. In case management in Thailand, a wide clinical spectrum of disease severity has been found. Human leptospirosis ranges in severity from a mild, self-limited febrile illness to a fulminant, life-threatening one. Most cases are uncomplicated, anicteric disease, with around 10 days of fever and a mortality of less than 1%. Uncomplicated disease is a major cause of morbidity, but rapid, reliable laboratory diagnosis is not widely available. In addition, the mild forms may be misdiagnosed because the clinical presentations are similar to those for several other infectious diseases.

It is estimated that 10% to 15% of leptospirosis cases show the most severe manifestations of the disease, known as Weil’s syndrome (jaundice-hemorrhage-renal failure), and are more likely to be recognized as leptospirosis based on signs and symptoms. This syndrome is an important cause of death, with a case-fatality rate of 10% to 12%. However, severe pulmonary forms of leptospirosis have been described in various geographic areas. These severe pulmonary forms are characterized by massive pulmonary hemorrhage and renal failure, with case-fatality rates of 50% to 70%. These forms have been given different designations, including adult respiratory distress syndrome (ARDS), severe pulmonary form of leptospirosis (SPFL), and pulmonary hemorrhage syndrome associated with leptospirosis (PHSL) (11 Trevejo RT, Rigau-Pérez JG, Ashford DA, McClure EM, Jarquín-González C, Amador JJ, et al. Epidemic leptospirosis associated with pulmonary hemorrhage—Nicaragua, 1995. J Infect Dis. 1998;178(5):1457–63., 2525 Silva JJ, Dalston MO, Carvalho JE, Setubal S, Oliveira JM, Pereira MM. Clinicopathological and immunohistochemical features of the severe pulmonary form of leptospirosis. Rev Soc Bras Med Trop. 2002;35(4):395–9.). According to a Rio meeting presentation, these challenges for clinical management in hospital intensive care units (ICUs) have been seen in the city of São Paulo, Brazil.

A critical point is to evaluate the prognostic factors of severe forms that require hospitalization. This is particularly important in emergency situations such as outbreaks associated with weather changes and flooding. Some of the Rio meeting participants suggested that the guidelines for clinical management prepared by experts in Brazil be made available to other countries. These guidelines include epidemiological criteria related to risk exposure in natural disasters; anamnesis and physical examination with chronology of signs and symptoms; warning signs and indications for hospital admission; diagnostic procedures with algorithms; clinical management in intensive care units; clinical support and antibiotic therapy; and hospital discharge criteria (2626 Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis. Leptospirose: diagnóstico e manejo clínico. Brasília: Ministério da Saúde; 2014.).

Fundamental knowledge gaps and challenges for research, technological development, and innovation

The main scientific knowledge gaps for the road map for leptospirosis are related to the prediction, detection, prevention, and clinical management of human cases. Challenges from the scientific point of view were presented by several Rio meeting participants. Aspects of RTDI were framed within the concepts of One Health and translational research. The presentations covered important aspects of biomedical research, emphasizing the etiological agents and their hosts.

Three meeting presentations illustrated possibilities for further developments, including whole genome applications for diagnosis and vaccines, as well as experimental models to understand the molecular mechanisms of leptospirosis pathogenesis. One presentation looked at how and why to type the agents of leptospirosis. The second presentation considered the genome of Leptospira interrogans serovar Copenhageni and the identification of potential targets for diagnosis and vaccines. The third examined the significance of understanding the relationship between leptospires and their reservoir hosts of infection.

Results from studies carried out in French overseas departments in the Caribbean (Guadeloupe and Martinique) and in the Indian Ocean (Mayotte) (2727 Bourhy P, Collet L, Lernout T, Zinini F, Hartskeerl RA, van der Linden H, et al. Human Leptospira isolates circulating in Mayotte (Indian Ocean) have unique serological and molecular features. J Clin Microbiol. 2012;50(2):307–11.) were presented at the Rio meeting. Data from more than 150 isolates from Guadeloupe and Martinique and more than 200 from Mayotte have identified new pathogens by serological and/or molecular techniques at the species level (Leptospira mayottensis), serovars (Tabaquite, Bajan, and unknown serovars), new genotypes, and sequence types. These data illustrate the biodiversity of Leptospira. Perspectives in this field should take into account the identification of the etiological agent by next-generation sequencing, RNA-based PCR assays, and the development of LPS-based molecular methods (2727 Bourhy P, Collet L, Lernout T, Zinini F, Hartskeerl RA, van der Linden H, et al. Human Leptospira isolates circulating in Mayotte (Indian Ocean) have unique serological and molecular features. J Clin Microbiol. 2012;50(2):307–11.

28 Bourhy P, Collet L, Brisse S, Picardeau M. Leptospira mayottensis sp. nov., a pathogenic species of the genus Leptospira isolated from humans. Int J Syst Evol Microbiol. 2014;64(Pt 12):4061–7.
-2929 Desvars A, Naze F, Vourc’h G, Cardinale E, Picardeau M, Michault A, et al. Similarities in Leptospira serogroup and species distribution in animals and humans in the Indian ocean island of Mayotte. Am J Trop Med Hyg. 2012;87(1):134–40.).

The pan-genome analysis of Leptospira species remains a key gap in identifying potential targets for diagnosis and in generating new vaccines (3030 Fouts DE, Matthias MA, Adhikarla H, Adler B, Amorim-Santos L, Berg DE, et al. What makes a bacterial species pathogenic?: comparative genomic analysis of the genus Leptospira. PLoS Negl Trop Dis. 2016;10(2):e0004403.). Results from several studies using L. interrogans serovar Copenhageni to explore genome sequences in search for candidates for diagnostic tests and vaccines and for a better understanding of pathogenesis were presented in Rio. Those studies covered: 1) the availability of the whole genome sequence of Copenhageni; 2) in silico analysis for protein selection; 3) the pipeline to obtain recombinant proteins; and 4) identification of novel extracellular membrane (ECM) binding proteins with a possible role in pathogenesis through adhesion to eukaryotic cells and their possible relations with molecular mechanisms of pathogenesis. Putative novel proteins and mechanisms of cell invasion possibly associated with adhesins that have been described in previous publications were also covered at the Rio meeting. The construction of chimeric proteins based on B/T lymphocytes epitopes or known immunoprotective regions is considered to be a promising strategy for vaccine candidates (3131 Silva LP, Fernandes LG, Vieira ML, de Souza GO, Heinemann MB, Vasconcellos SA, et al. Evaluation of two novel leptospiral proteins for their interaction with human host components. Pathog Dis. 2016;74(5).).

The biodiversity of leptospires is likely to be associated with a large diversity of animal hosts in the mammal clade. Rodents are the universal reservoirs, while man is an accidental host, in which the infection may be lethal. Results obtained from experimental infection in rodents have been key for understanding the relationships between Leptospira and the animal hosts, according to data from recent publications that were covered during the meeting. The main findings dealt with different patterns of renal tissue changes and distribution of antigens, with modulation of gene and protein expression by leptospires in response to mammalian host signs. Understanding the mechanisms involved in leptospirosis pathogenesis and immunity is crucial for new therapeutic alternatives and vaccines. Information about gene and protein expression modulation by leptospires in response to mammalian host signals represents a step forward for further developments (3232 Pereira MM, Da Silva JJ, Pinto MA, Da Silva MF, Machado MP, Lenzi HL, et al. Experimental leptospirosis in marmoset monkeys (Callithrix jacchus): a new model for studies of severe pulmonary leptospirosis. Am J Trop Med Hyg. 2005;72(1):13–20., 3333 Caimano MJ, Sivasankaran SK, Allard A, Hurley D, Hokamp K, Grassmann AA, et al. A model system for studying the transcriptomic and physiological changes associated with mammalian host-adaptation by Leptospira interrogans serovar Copenhageni. PLoS Pathog. 2014;10(3):e1004004.).

ROAD MAP

Table 2 summarizes the leptospirosis road map and encompasses the report of countries’ needs by relevant topic according to the survey, identified scientific challenges, ongoing research to address those needs, and recommendations. The health policy recommendations should be taken into account by decisionmakers, government officials, and PAHO/WHO. The priorities for research, technological development, and innovation (RTDI) should be considered by research institutions, universities, and stakeholders. The list of general recommendations is presented in Supplementary File 2.

TABLE 2
Summary of road map for leptospirosis research and health policies in Latin America

CONCLUSIONS

The conclusions listed below were reached by consensus in the group discussions at the Rio meeting:

  1. Leptospirosis is not considered to be a “tool-ready” disease for global initiatives. Surveillance programs are not equipped with the necessary tools for early detection, prevention, and follow-up strategies. This is despite the wide geographic distribution of leptospirosis and its impact in terms of incidence, morbidity, and mortality.

  2. The scenario presented by data from the Americas, Europe, Asia, Africa, and New Zealand corroborates the complexity of transmission cycles, which involve a range of animal carriers, several species and serovars as etiological agents, and different environmental factors. This complexity presents biological, environmental, and scientific challenges.

  3. The One Health approach should be considered in addressing further developments and initiatives for prevention, control, and the ultimate goal of saving lives.

  4. There are technical and scientific knowledge gaps that hinder epidemiological surveillance and that cut across leptospirosis clinical management, prevention, and control.

  5. Identified knowledge gaps should be addressed at different levels of health policies and supported by new scientific developments.

Acknowledgments

We thank all the Rio meeting participants, whose contributions made it possible to develop the road map for leptospirosis research and health policies in Latin America. In particular, we would like to recognize all the members of the organizing and scientific committees and the country representatives for their valuable support: A. Ko, C. Munoz-Zanzi, C. Schneider, D. Galan, E. Bertherat, E. Caldas, E. Vazquez, F. Costa, F. Mendigaña Paez, F. Pinna, H. Cedeño, J. Arrebato, J. Barbosa, J. Benschop, J. Nally, J. Navarro, J. Martinez, L. Contretas, L. Geffner, L. Fonseca, M. Jancloes, M. Pereira, M. Picardeau, O. Cosivi, P. Buss, R. Hartskeerl, R. Lima, R. Velasquez, S. Aldighieri, S. Nishioka, S. Valéria, W. Savino, and Y. Salazar.

Funding

Sponsorship and support for the meeting came from the Ministry of Health of Brazil (Oswaldo Cruz Institute/FIOCRUZ, the Secretariat of Health Surveillance, and the Secretariat of Science and Technology), the Pan American Health Organization (PAHO/WHO), and GLEAN.

Conflicts of Interest

The authors declare they have no competing interests.

Disclaimer

Authors hold sole responsibility for the views expressed in the manuscript, which may not necessarily reflect the opinion or policy of the RPSP/PAJPH or PAHO.

REFERENCES

  • 1
    Trevejo RT, Rigau-Pérez JG, Ashford DA, McClure EM, Jarquín-González C, Amador JJ, et al. Epidemic leptospirosis associated with pulmonary hemorrhage—Nicaragua, 1995. J Infect Dis. 1998;178(5):1457–63.
  • 2
    Johnson MA, Smith H, Joseph P, Gilman RH, Bautista CT, Campos KJ, et al. Environmental exposure and leptospirosis, Peru. Emerg Infect Dis. 2004 Jun;10(6):1016–1022. doi: 10.3201/eid1006.030660.
    » https://doi.org/10.3201/eid1006.030660
  • 3
    Sehgal S, Sugunan A, Vijayachari P. Outbreak of leptospirosis after the cyclone in Orissa. Natl Med J India. 2002;15(1):22–3.
  • 4
    Victoriano AFB, Smythe LD, Gloriani-Barzaga N, Cavinta LL, Kasai T, Limpakarnjanarat K, et al. Leptospirosis in the Asia Pacific region. BMC Infect Dis. 2009;9:147.
  • 5
    Amilasan AT, Ujiie M, Suzuki M, Salva E, Belo MCP, Koizumi N, et al. Outbreak of leptospirosis after flood, the Philippines, 2009. Emerg Infect Dis. 2012;18(1):91–4.
  • 6
    Schneider MC, Nájera P, Aldighieri S, Bacallao J, Soto A, Marquiño W, et al. Leptospirosis outbreaks in Nicaragua: identifying critical areas and exploring drivers for evidence-based planning. Int J Environ Res Public Health. 2012;9(11):3883–910.
  • 7
    Ko AI, Reis MG, Dourado CMR, Johnson Jr WD, Riley LW. Urban epidemic of severe leptospirosis in Brazil. Lancet. 1999;354(9181):820–5.
  • 8
    Bacallao J, Schneider MC, Najera P, Aldighieri S, Soto A, Marquiño W, et al. Socioeconomic factors and vulnerability to outbreaks of leptospirosis in Nicaragua. Int J Environ Res Public Health. 2014;11(8):8301–18.
  • 9
    Caminiti RT, Romaní FR, Wong P, Villaverde JA. Prácticas laborales de riesgo en cultivadores de arroz del valle del Alto Mayo, Región San Martín, Perú. Rev Peru Epidemiol 2011;15(1) [6 pp.].
  • 10
    Benschop J, Heuer C, Jaros P, Collins-Emerson J, Midwinter A, Wilson P. Sero-prevalence of leptospirosis in workers at a New Zealand slaughterhouse. N Z Med J. 2009;122(1307):39–47.
  • 11
    Costa F, Hagan JE, Calcagno J, Kane M, Torgerson P, Martinez-Silveira MS, et al. Global morbidity and mortality of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2015;9(9):1–19.
  • 12
    Schneider MC, Jancloes M, Buss DF, Aldighieri S, Bertherat E, Najera P, et al. Leptospirosis: a silent epidemic disease. Int J Environ Res Public Health. 2013;10(12):7229–34.
  • 13
    World Health Organization. Global plan to combat neglected tropical diseases 2008–2015. Geneva: WHO; 2007.
  • 14
    World Health Organization. Accelerating work to overcome the global impact of neglected tropical diseases: a roadmap for implementation. Geneva: WHO; 2012.
  • 15
    Torgerson PR, Hagan JE, Costa F, Calcagno J, Kane M, Martinez-Silveira MS, et al. Global burden of leptospirosis: estimated in terms of disability adjusted life years. PLoS Negl Trop Dis. 2015;9(10):e0004122.
  • 16
    Pan American Health Organization. Regional Core Health Data Initiative. Available from: http://www.paho.org/hq/index.php?option=com_tabs&view=article&id=2151&Itemid=3632&lang=en Accessed 16 August 2016.
    » http://www.paho.org/hq/index.php?option=com_tabs&view=article&id=2151&Itemid=3632&lang=en
  • 17
    Schneider MC, Leonel DG, Hamrick PN, Caldas EP, Velásquez RT, Mendigaña Paez FA, et al. Leptospirosis in Latin America: exploring the first set of regional data. Rev Panam Salud Publica.2017;41:e81.
  • 18
    Allan KJ, Biggs HM, Halliday JEB, Kazwala RR, Maro VP, Cleaveland S, et al. Epidemiology of leptospirosis in Africa: a systematic review of a neglected zoonosis and a paradigm for “One Health” in Africa. PLoS Negl Trop Dis. 2015;9(9):e0003899.
  • 19
    Petrakovsky J, Bianchi A, Fisun H, Nájera-Aguilar P, Pereira MM. Animal leptospirosis in Latin America and the Caribbean countries: reported outbreaks and literature review (2002–2014). Int J Environ Res Public Health. 2014;11(10):10770–89.
  • 20
    Schneider MC, Najera P, Pereira MM, Machado G, dos Anjos CB, Rodrigues RO, et al. Leptospirosis in Rio Grande do Sul, Brazil: an ecosystem approach in the animal-human interface. PLoS Negl Trop Dis. 2015;9(11):e0004095.
  • 21
    Srikram A, Zhang K, Bartpho T, Lo M, Hoke DE, Sermswan RW, et al. Cross-protective immunity against leptospirosis elicited by a live, attenuated lipopolysaccharide mutant. J Infect Dis. 2011 Mar 15;203(6):870–9. doi: 10.1093/infdis/jiq127.
    » https://doi.org/10.1093/infdis/jiq127
  • 22
    Ko AI, Goarant C, Picardeau M. Leptospira: the dawn of the molecular genetics era for an emerging zoonotic pathogen. Nat Rev Micro. 2009;7(10):736–47.
  • 23
    Sonrier C, Branger C, Michel V, Ruvoën-Clouet N, Ganière JP, André-Fontaine G. Evidence of cross-protection within Leptospira interrogans in an experimental model. Vaccine. 2000;19(1):86–94.
  • 24
    Dobigny G, Garba M, Tatard C, Loiseau A, Galan M, Kadaoure I, et al. Urban market gardening and rodent-borne pathogenic Leptospira in arid zones: a case study in Niamey, Niger. PLoS Negl Trop Dis. 2015;9(10):e0004097.
  • 25
    Silva JJ, Dalston MO, Carvalho JE, Setubal S, Oliveira JM, Pereira MM. Clinicopathological and immunohistochemical features of the severe pulmonary form of leptospirosis. Rev Soc Bras Med Trop. 2002;35(4):395–9.
  • 26
    Brasil, Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de Vigilância das Doenças Transmissíveis. Leptospirose: diagnóstico e manejo clínico. Brasília: Ministério da Saúde; 2014.
  • 27
    Bourhy P, Collet L, Lernout T, Zinini F, Hartskeerl RA, van der Linden H, et al. Human Leptospira isolates circulating in Mayotte (Indian Ocean) have unique serological and molecular features. J Clin Microbiol. 2012;50(2):307–11.
  • 28
    Bourhy P, Collet L, Brisse S, Picardeau M. Leptospira mayottensis sp. nov., a pathogenic species of the genus Leptospira isolated from humans. Int J Syst Evol Microbiol. 2014;64(Pt 12):4061–7.
  • 29
    Desvars A, Naze F, Vourc’h G, Cardinale E, Picardeau M, Michault A, et al. Similarities in Leptospira serogroup and species distribution in animals and humans in the Indian ocean island of Mayotte. Am J Trop Med Hyg. 2012;87(1):134–40.
  • 30
    Fouts DE, Matthias MA, Adhikarla H, Adler B, Amorim-Santos L, Berg DE, et al. What makes a bacterial species pathogenic?: comparative genomic analysis of the genus Leptospira PLoS Negl Trop Dis. 2016;10(2):e0004403.
  • 31
    Silva LP, Fernandes LG, Vieira ML, de Souza GO, Heinemann MB, Vasconcellos SA, et al. Evaluation of two novel leptospiral proteins for their interaction with human host components. Pathog Dis. 2016;74(5).
  • 32
    Pereira MM, Da Silva JJ, Pinto MA, Da Silva MF, Machado MP, Lenzi HL, et al. Experimental leptospirosis in marmoset monkeys (Callithrix jacchus): a new model for studies of severe pulmonary leptospirosis. Am J Trop Med Hyg. 2005;72(1):13–20.
  • 33
    Caimano MJ, Sivasankaran SK, Allard A, Hurley D, Hokamp K, Grassmann AA, et al. A model system for studying the transcriptomic and physiological changes associated with mammalian host-adaptation by Leptospira interrogans serovar Copenhageni. PLoS Pathog. 2014;10(3):e1004004.

Publication Dates

  • Publication in this collection
    19 Feb 2018

History

  • Received
    12 Oct 2016
  • Accepted
    08 Feb 2017
Organización Panamericana de la Salud Washington - Washington - United States
E-mail: contacto_rpsp@paho.org